Motley Fool
1 Cancer Stock on Buyout Watch in 2022
The pharmaceutical industry appears poised for a record-breaking level of merger and acquisition (M&A) activity in 2022. First, Pfizer (NYSE: PFE) and Moderna are both flush with cash thanks to their novel coronavirus vaccines. Third, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Gilead Sciences, Johnson & Johnson, Merck, Moderna, Pfizer, and Sanofi are all expected to pursue bolt-on acquisitions next year to flesh out their clinical pipelines and product portfolios.
